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Abstract
Background: H7N9 continues to cause human infections and remains a pandemic concern. Understanding the
economic impacts of this novel disease is important for making decisions on health resource allocation, including
infectious disease prevention and control investment. However, there are limited data on such impacts.
Methods: Hospitalized laboratory-confirmed H7N9 patients or their families in Jiangsu Province of China were
interviewed. Patients’ direct medical costs of hospitalization were derived from their hospital bills. A generalized
linear model was employed to estimate the mean direct medical costs of patients with different characteristics.
Results: The mean direct cost of hospitalization for H7N9 was estimated to be ¥ 71 060 (95 % CI, 48 180–104 820),
i.e., US$ 10 996 (95 % CI, 7 455–16 220), and was ¥12 060 (US$ 1 861), ¥136 120 (US$ 21 001) and ¥218 610 (US$ 33
728) for those who had mild or severe symptoms or who died, respectively. The principal components of the total
fees differed among patients with different disease severity, although medication fees were always the largest
contributors. Disease severity, proportion of reimbursement and family member monthly average income were
identified as the key factors that contributed to a patient’s direct medical cost of hospitalization.
Conclusions: The direct medical costs of hospitalized patients with H7N9 are significant, and far surpass the annual
per capita income of Jiangsu Province, China. The influencing factors identified should be taken into account when
developing related health insurance policies and making health resource allocation.
Trial registration: Not applicable. This is a survey study with no health care intervention implemented on human
participants.
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Background
A novel avian-origin influenza A (H7N9) virus has caused
severe human infections in China since February 2013 [1].
As of November 13 2015, a total of 681 laboratory-
confirmed cases of human infection with H7N9, including
at least 275 deaths, have been reported to World Health
Organization (WHO) [2]. Imported cases have been
reported in Hong Kong [3], Taiwan [4], Canada [5] and
Malaysia [6]. Limited human-to-human transmissions
were observed and raised a pandemic concern [7]. Most
of the reported human infections have been severe, with
76.6 % admitted to an intensive care unit (ICU), and
27.0 % dying [1]. Over 60 % of cases had underlying
medical conditions [8]. These severe symptoms are
associated with high direct medical costs. Though
understanding the economic burden of H7N9 disease
is imperative for understanding the societal and individual
impacts of this disease and deciding corresponding health
resources allocation, data on this issue are limited. Qi X. et
al calculated the direct medical costs for H7N9 patients
using formulae, the parameters for which were estimated
by experienced hospital financial officers and doctors, from
the epidemiological data or from previous publications [9].
In this study, we measured the actual direct medical cost
of hospitalized H7N9 patients and its components accord-
ing to the inventories of patients’ hospitalization fees, and
analyzed the influencing factors for the costs. This study
describes the actual economic burden of hospitalized
patients with H7N9 in order to present evidence on the
cost-effectiveness of H7N9 prevention and control.
Methods
Subjects
This research was conducted in Jiangsu Province from
August to September 2014. All the laboratory-confirmed
H7N9 patients who had been hospitalized before the
study period were included. Cases were categorized by
severity into three groups (mild, severe and fatal).
According to the Diagnosis and Treatment Guideline for
Human Infections with H7N9 released by the National
Health and Family Planning Commission of China (Year
2014), cases with one of the following criteria were defined
as having severe infection: a. Leafy lesions or lesions pro-
gress >50 % in 48 h indicated by X-ray chest radiograph; b.
Dyspnea, breathing rate >24 times/min; c. Severe hypox-
emia, patients’ SpO2 ≤ 92 % under oxygen flow of 3–5
litters/min; d. Shock, ARDS (Acute Respiratory Distress
Syndrome) or MODS (Multiple Organ Dysfunction
Syndrome). Furthermore, patients were grouped into
Northern or Southern district based on their street
address to study the potential influence of a district’s
economic level on medical cost of disease. Generally, both
the Per Capita GDP and Per Capita Annual Income are
higher in the southern district compared with the
northern district of Jiangsu Province, China.
Information collection
A standardized questionnaire was used to collect informa-
tion. Trained staff from local centers for disease control
and prevention in Jiangsu Province collected data on
demographic characteristics, health insurance, proportion
of reimbursement and household income through inter-
viewing cases or their family members. Patients’ disease
severity were collected via a national system for reporting
of notifiable infectious diseases, which were judged and
reported by clinical doctors.
Direct medical costs of hospitalization
Direct medical costs of hospitalized patients infected with
H7N9 were derived from patients’ hospital bills. The total
cost consists of medication, examination, laboratory tests,
treatment, medical consumables, ward bed, nursing and
other fees. Examination includes ultrasonography, Com-
puted Tomography (CT), Magnetic Resonance Imaging
(MRI), digital imaging and pathological examinations.
Laboratory tests include blood, urine, feces and respiratory
samples’ testing and culture. Treatment includes diagno-
sis, monitoring, blood transfusion, oxygen therapy and
surgery procedures.
Statistical analyses
Medians and interquartile ranges (IQRs) were calculated
for various medical fees and their accounted proportions.
Medical fees were compared between patients with differ-
ent characteristics, using Mann–Whitney U tests (for 2
groups) or Kruskal-wallis H tests (for multiple groups). All
study variables with P < 0.2 in univariate analyses were
included in multivariate analyses in order to investigate as
many potential variables as possible. A generalized linear
model (Gamma with log link) was employed to analyze
the association between selected variables and patients’
direct medical costs. Both main effects and interactions of
selected variables were analyzed. Model’s goodness of fit
was compared using Deviance and Chi-Square (per degree
of freedom) to choose the best model. Then the selected
best model was used to estimate the grand mean of
direct medical costs of hospitalized patients infected
with H7N9 avian influenza, and that of patients with
different characteristics.
Results
Up to 31 July 2014, a total of 52 laboratory-confirmed
H7N9 patients were admitted to hospitals and were
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reported in Jiangsu Province. Twenty-one of them were
reported in 2013 and the others in 2014. All of them were
included in this study. Male patients accounted for 76.9 %.
The median age was 54.5 years (IQR, 36.25–67.50). Among
the patients, 4 cases were mild, 27 cases were severe and
21 cases died. The observed median hospitalization fee of
all patients studied was ¥ 122 260 (IQR, 60 710–310 220),
i.e., US$ 18 858, (IQR, 9 364-47 851; exchange rate, 6.48).
The hospitalization fee increased with patient’s disease
severity. The median was ¥ 12 790, ¥ 96 780 and ¥ 228 650
for mild, severe and dead patients respectively (P < 0.0001).
In addition, medication fees, laboratory testing fees, treat-
ment fees and examination fees all increased with patient’s
disease severity (P < 0.05) (Fig. 1a, Table 1).
Medication costs accounted for the largest portion of
the hospitalization fees (median proportion, 53.5 %),
followed by treatment costs (median proportion, 14.8 %)
and laboratory testing costs (median proportion, 11.9 %).
The principal components of the hospitalization fees
differed among patients with different disease severity,
although medication fees were always the highest pro-
portion (55.1, 55.2 and 49.3 % for mild, severe and dead
patients respectively, P = 0.868). The medication cost
was followed by laboratory testing cost (16.3 %) and
examination cost (4.6 %) in mild patients, by laboratory
testing cost (13.2 %) and treatment cost (11.2 %) in
severe patients and by treatment cost (22.9 %) and
medical consumables cost (12.6 %) in dead patients. The
proportion of laboratory testing costs and examination
costs declined, while the proportion of treatment costs
and medical consumables cost increased with patient’s
disease severity (P < 0.05) (Fig. 1b, Table 1).
Most of the medication used was western medication
(median proportion, 99.7 %), with no significant
difference among patients with different disease sever-
ity (P = 0.420). The median western medication costs
were ¥ 3 520, ¥55 750 and ¥137 220 for mild, severe
and dead patients (P = 0.001). Antibiotics, antivirals,
glucocorticoids and immunoglobulin costs all increased
with patients’ disease severity (P < 0.05) (Fig. 1c, Table 1).
In mild patients, antibiotic expenses accounted for
over a half (proportion median, 57.6 %) of the medica-
tion fee and antivirals expense accounted for 7.5 %.
These proportions declined with patients’ disease sever-
ity. Proportion of antibiotics expense decreased to 31.4
and 13 % for severe and dead patients, and antivirals
Fig. 1 Direct medical costs (thousand yuan, RMB) and proportions of main components for different hospitalized H7N9 patients. a Direct medical
costs of hospitalization and its main components in different patients; b Proportions of main medical cost components in different patients;
c Medications costs in different patients; d Proportions of medications in different patients
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Table 1 Direct medical costs (RMB, thousand Yuan) of hospitalization in different H7N9 patients
All patients (n = 52) Mild (n = 4) Severe (n = 27) Dead (n = 21) P* P**
Median (IQR) Proportion, %,
median (IQR)
Median (IQR) Proportion, %,
median (IQR)
Median (IQR) Proportion, %,
median (IQR)
Median (IQR) Proportion, %,
median (IQR)
Total fee 122 260 (60 710–310 220) 100 12 790 (3 320–19 750) 100 96 780 (56 780–287 140) 100 228 650 (116 410–549 520) 100 <0.0001 –
Examination 8 420 (2 920–17 320) 5.0 (2.5–10.6) 530 (150–1 510) 4.6 (3.5–9.4) 8 660 (3 840–14 700) 7.3 (3.2–11.6) 13 900 (3 400–21 540) 2.8 (1.6–9.9) 0.011 0.092
Lab testing 15 350 (8 520–35 570) 11.9 (9.1–14.9) 1 910 (290–3 390) 16.3 (7.8–19.4) 14 600 (8 470–27 950) 13.2 (10.2–15.3) 25 530 (11 120–65 980) 9.7 (7.6–11.5) 0.002 0.009
Medication 63 250 (27 420–212 700) 53.5 (40.1–60.1) 8 080 (1 820–10 170) 55.1 (34.8–65.3) 61 130 (21 280–151 040) 55.2 (47.0–59.8) 137 410 (54 290–345 040) 49.3 (38.0–60.6) 0.001 0.868
Western
medication
58 390 (22 050–190 890) 99.7 (90.6–100.0) 3 520 (780–8 890) 83.6 (36.0–95.9) 55 750 (20 950–146 220) 99.7 (94.6–100.0) 137 220 (54 290–345 030) 99.7 (91.1–100.0) 0.001 0.420
TCMa 340 (10–2 490) 0.3(0 .0–3.4) 300 (20–1 700) 12.5 (2.2–19.5) 330 (10–2 420) 0.3 (0.0–3.3) 350 (10–4 870) 0.3 (0.0–2.5) 0.812 0.358
Antibiotics 12 880 (5 370–38 210) 20.8 (11.1–36.3) 2 740 (530–4 950) 57.6 (22.4–68.3) 13 260 (5 870–39 200) 31.4 (16.1–39.0) 19 060 (7 650–43 730) 13.0 (8.1–30.5) 0.014 0.018
Antiviral 1 930 (840–4 130) 2.5 (0.9–7.8) 390 (20–790) 7.5 (1.7–14.2) 1 820 (980–4 140) 2.9 (1.1–8.0) 2 990 (1 390–4 780) 1.2 (0.6–5.7) 0.016 0.333
Glucocorticoids 2 320 (340–8 560) 2.3 (0.4–13.3) 0 (0–1 930) 0.0 (0.0–19.0) 1 140 (270–6 700) 1.3 (0.3–13.6) 4 660 (1 620–22 830) 4.1 (1.6–13.0) 0.002 0.072
Immunoglobulin 13 880 (0–33 400) 10.4 (0.0–24.4) 0 0.0 5 960 (0–39 100) 10.4 (0.0–31.6) 23 040 (8 290–39 780) 17.0 (9.4–21.5) 0.014 0.025
Treating 13 860 (5 610–65 210) 14.8 (8.3–23.8) 120 (70–2 500) 2.9 (0.8–12.9) 8 770 (4 600–32 350) 11.2 (7.7–18.3) 54 450 (16 170–200 570) 22.9 (14.8–29.8) <0.0001 0.002
Medical
Consumables
1 010 (0–16 510) 2.4 (0.0–12.2) 300 (100–2 290) 3.7 (2.2–11.8) 150 (0–6 070) 0.2 (0.0–5.9) 21 630 (0–88 810) 12.6 (0.0–19.1) 0.025 0.020
Sick bed 2 400 (1 340–3 990) 1.4 (0.7–3.2) 320 (1 650–5 260) 4.4 (1.1–14.2) 3 040 (1 430–5 150) 2.1 (1.2–4.3) 2 240 (1 410–3 520) 0.8 (0.5–1.4) 0.021 0.001
Nursing 2 390(790–6 270) 1.5 (0.7–3.3) 340 (160–660) 5.3 (0.9–18.9) 3 170 (1 250–6 620) 2.6 (1.1–4.8) 2 180 (1 490–7 850) 1.3 (0.7–1.5) 0.050 0.033
Other fees 100 (0–810) 0.1 (0.0–1.1) 10 (0–70) 0.1 (0.0–0.3) 310 (70–2 400) 0.4 (0.1–2.0) 60 (0–260) 0.0 (0.0–0.2) 0.022 0.032
*P for fee medians comparisons among patients with different clinical outcomes, using Kruskal-wallis H test















expense decreased to 2.9 and 1.2 % respectively. In con-
trast, the proportion of immunoglobulin and glucocorti-
coids expense increased with patient’s disease severity.
Other drugs expense increased with patient’s disease se-
verity as well (Fig. 1d, Table 1).
Stratified analyses indicated that significant difference
in hospitalization fee was not found among patients with
different types of health insurances (P = 0.755), but was
found among patients with different proportions of re-
imbursement (P = 0.033). Hospitalization fees were sig-
nificantly higher in patients from the southern district of
Jiangsu Province (P = 0.044) and obviously lower in pa-
tients with a family member monthly average income of
less than ¥ 1 000 (P = 0.135). A significant higher
hospitalization fee was observed in female patients (P =
0.020) compared with male patients. Nevertheless, no
significant difference was observed among patients of
different ages ((P = 0.945) (Table 2).
All variables with P < 0.2 aforementioned were in-
cluded in the multivariate analyses using a generalized
linear model (Gamma with log link). Finally, the com-
bination of disease severity, proportion of reimburse-
ment and family member monthly average income was
found to be associated with patients hospitalization fee
with best goodness of fit (Additional file 2: Table S1).
The fitted model estimated that the mean direct medical
costs of hospitalized patients infected with H7N9 was ¥71
060 (95 % CI, 48 180–104 820), which was 2.18 times the
annual per capita disposable income of urban residents,
and 5.23 times the annual per capita net income of rural
residents of Jiangsu Province, China in 2013 [10]. As of
Nov. 13 2015, a total of 78 human infections with H7N9
were confirmed and 74 of them were hospitalized in
Jiangsu Province. Thus, the total direct medical costs of
hospitalized H7N9 patients in Jiangsu Province were esti-
mated to be ¥ 5 258 440 (95 % CI, 3 565 320–7 756 680),
i.e., US$ 811 594 (95 % CI, 550 276–1 197 176).
The mean hospitalization fees of patients with different
disease severity were also estimated by the fitted model.
The means were estimated to be ¥12 060, ¥136 120 and
¥218 610 for mild, severe and dead patients, respectively.
In addition, mean hospitalization fees of patients with
different proportions of reimbursement and family mem-
ber monthly average income were estimated by the fitted
model as well. Hospitalization fees were significantly
higher in patients with 100 % reimbursement and signifi-
cantly lower in patients with family member monthly
average income lower than ¥ 1 000 compared with the
mean fees for all patients (P = 0.026 and 0.002) (Table 3).
Discussion
This study measured the direct medical costs associated
with hospitalization with H7N9 avian influenza in
Jiangsu Province, China. The direct medical costs were
found to be significant, far surpassing the annual per
capita income for residents of Jiangsu Province. This
disparity in costs and income was especially high in
those who died from the infection. The total economic
burden would be even higher if patients’ direct medical
costs before admission, direct non-medical expenses and
indirect economic losses due to deaths or missed work-
ing time were included [9]. The mean direct cost of
hospitalization with H7N9 (US$ 10 969) estimated in
this research is much higher than that of hospitalization
Table 2 Univariate analysis of the factors associated with direct
medical cost (RMB) of hospitalized H7N9 patients
Selected
variables
Frequency Median of total fee
(interquartile range)
P*
Overall 52 122 260 (60 710–310 220) N.A.
Severity and outcome <0.0001
Mild 4 12 780 (3 320–19 750)
Severe 27 96 780 (56 780–287 140)
Dead 21 228 650 (116 410–549 520)
Gender 0.020
Male 40 100 110 (52 190–265 010)
Female 12 259 880 (116 410–544 590)
Age, years 0.945
<34 10 201 960 (21 750–460 340)
35–64 27 108 420 (64 350–277 420)
>=65 15 123 820 (80 350–310 210)
Districta 0.044
Northern 12 84 840 (37 230–125 650)
Southern 39 138 360 (76 740–460 660)
Health insurancea 0.755
None 5 96 780 (57 360–287 140)
URBMI 28 92 210 (52 190–271 140)




<50 % 7 96 780 (38 800–128 980)
50–79 % 10 101 140 (53 990–228 650)
80–99 % 8 87 270 (29 700–193 050)





<1 4 67 770 (37 870–167 950)
1–3 10 303 340 (120 700–606 530)
3–5 15 105 460 (77 960–165 360)
5–10 14 131 640 (32 330–460 340)
>=10 6 302 140 (123 820–1103 550)
*Mann–Whitney U test (for 2 groups) or Kruskal-wallis H test (for
multiple groups)
aThere are 1, 7 and 3 missing data in District, Health insurance and Family
member monthly average income respectively
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associated with seasonal influenza (US$ 1 797) [11] and
the healthcare costs per patient with severe acute re-
spiratory syndrome (SARS) in Beijing (US$ 1 886) most
likely due to higher rates of ICU admission and death
[12, 13] and the use of more expensive modern medical
devices [14]. In addition, the longer hospitalization
duration of H7N9 patients (compared with H5N1 and
pH1N1, P < 0.001) could also be responsible for the
higher hospitalization fee [15]. According to the mean
cost (US$ 10 969; 95 % CI, 7 356–16 003) determined in
this study, we estimate that the total direct medical costs
associated with hospitalization of H7N9 patients across
China as of November 13, 2015 (681 patients reported,
assuming the hospitalization rate is 92.9 % which is the
rate found in Jiangsu Province) is about US$ 6 932 408
(95 % CI, 4 648 992–10 113 896).
Local governments provided additional financial support
for patients infected with H7N9 at the beginning of the
H7N9 epidemic. In this study, over a half (51.9 %) of the
patients got full reimbursement of their hospitalization
fees, and about 67 and 87 % of the patients got at least 80
and 50 % of their hospitalization fees reimbursed. This
alleviated the actual economic burden of H7N9 patients
and their families greatly. However, this additional finan-
cial support was not continued. We found in our study
that hospitalization fees of patients with family member
monthly average income lower than ¥ 1 000 was signifi-
cantly lower than the average even after adjusting for
disease severity and reimbursement proportion. This is
because, for the low income group, even though the health
insurance can provide some financial protection, the co-
payment required is still too high for many to afford [16].
Thus, policies and regulations should be made to provide
more financial support for low-income groups who
contract H7N9 and other similar severe infectious
diseases. In addition, patients with full reimbursement
were found to have a significantly higher hospitalization
fee compared with the average after adjusting for disease
severity and family member average income. This should
also be taken into account when making related policies
and regulations in order to avoid unnecessary medical
costs, as it has been reported that reimbursement restric-
tions had a positive impact on enhancing the efficiency of
antihypertensive prescribing [17].
The mean direct medical costs of hospitalized H7N9
patients were found to be ¥12 060 (US$1 861), ¥136 120
(US$21 006) and ¥218 610 (US$33 736) (estimated by
model), or ¥12 790 (US$1 974), ¥96 780 (US$14 935)
and ¥228 650 (US$35 285) (medians observed) for mild,
severe and dead cases respectively in this study. Qi X. et
al indirectly calculated the direct medical costs of H7N9
patients in China using parameters estimated by
experienced hospital financial officers and doctors. Their
results show that the mean cost for each patient was ¥10
117 (US$ 1 619) for mild patients, ¥139 323 (US$22
292) for severe cases without death and ¥205 976
(US$32 956) for severe cases with death [9], which are
comparable with our data particularly as it should be
noted that the direct medical costs calculated by Qi X et
al were the total costs across a patients’ whole disease
Table 3 Estimated direct medical cost (RMB) of hospitalization for H7N9 patients with different characteristics
Selected variables B P* Estimated Mean (95 % CI) P**
Severity
Mild Ref. N.A. 12 060 (4 710–30 860) <0.0001
Severe 2.424 <0.0001 136 120 (88 830–208 580) 0.557
Dead 2.897 <0.0001 218 610(134 200–356 100) 0.013
Reimbursement proportion
<50 % Ref. N.A. 46 010 (21 480–98 570) 0.276
50–79 % 0.340 0.526 64 670 (32 060–130 470) 0.415
80–99 % 0.233 0.667 58 060 (27 900–120 840) 0.415
100 % 1.166 0.012 147 630 (92 610–235 340) 0.026
Family member monthly average income (RMB, thousand yuan)
<1 Ref. N.A. 22 250 (9 150–54 130) 0.002
1–3 1.691 0.001 120 770 (64 890–224 770) 0.613
3–5 1.236 0.012 76 600 (47 320–123 990) 0.730
5–10 1.124 0.020 68 460 (41 430-113 110) 0.662
>=10 1.755 0.002 128 620 (56 990-290 320) 0.613
Dependent Variable: Total fee
Model: (Intercept), severity, Reimbursement proportion, Family member monthly average income
Grand mean (95 % CI): 71 060 (48 180-104 820)
*P value for coefficient B
**P value for estimated mean compared with grand mean
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course, while the costs we investigated here were only
hospitalization fees. Thus, it is reasonable to infer that
the cost of hospitalization accounts for an overwhelming
majority of a patient’s total medical cost. In addition, the
difference in medical cost between Jiangsu Province and
other districts of China should not be overlooked. For
example, New Cooperative Medical Scheme, one of the
major types of health insurance in China, has provincial
differences in funding [16]. This difference could further
lead to provincial differences in medical cost, as the
reimbursement rate is found to influence the direct
medical cost of hospitalization in this study.
Medication, treatment and laboratory testing expenses
comprised the major part (80.2 %) of direct medical cost
of hospitalization with H7N9; a finding similar with that
of seasonal influenza-related hospitalizations, where
therapeutics and diagnostics were the two largest
components of direct medical cost, comprising 57 and
23 %, respectively [11].
The molecular mechanisms of traditional Chinese
medicine (TCM) for the treatment of influenza virus
infection, including H7N9, have been indicated by
computational approaches [18]. A preliminary study
suggested that duration of TCM therapy might has an
inverse association with patient’s critical outcome
[19]. The Diagnosis and Treatment Guideline for Human
Infections with H7N9 released by National Health and
Family Planning Commission of China also recommend
TCM therapy. However, TCM expense was found to be
quite low in this studied patients group. Further studies
should be conducted to establish the evidence on the
effectiveness of TCM therapy, further facilitating TCM
administration.
We found that other drugs expense (other than anti-
biotics, antivirals, glucocorticoids and Immunoglobu-
lin) accounted for a large proportion (over a half ) of
hospitalization fees for severe or dead patients. The
proportion of immunoglobulin expense was much
lower (no more than 17 %). In the study of Qi X. et al,
other drugs expense was estimated to be ¥270 per day
for mild patients and ¥1 600 per day for severe
patients, which was consistent with our findings. How-
ever, they estimated the expense of immunoglobulin to
be ¥2 500 per day, which is seriously overestimated
according to our observed data [9].
The expense of glucocorticoids was found to in-
crease with patients’ disease severity in this study.
However, glucocorticoids were found to enhance rep-
lication of influenza viruses [20] and a research from
Vietnam indicated that no significant effectiveness
for survival was observed among H5N1 patients
treated with methylprednisolone [21]. Thus, more
evidence is needed to guide clinical administration of
glucocorticoids.
There are limitations in our study. First, only direct
medical cost of hospitalization was described. Knowing
the medical expenses before patients’ admission and the
indirect economic losses associated with the loss of work-
ing time for H7N9 patients and their family members
would present a more complete portrayal of the economic
burden of this disease [22]. Second, the sample size is
small, especially for mild patients, although we have
included all mild patients with hospitalization in Jiangsu
Province during the study period. The special disease
spectrum of H7N9 infection (most are severe) or
difficulties in identifying mild patients (no comprehensive
administration of H7N9 test in influenza-like-illness
outpatients) might be responsible [23].
Conclusion
In conclusion, this study described the actual direct
medical cost of hospitalization with H7N9 and the main
components of the cost, helping us better understand the
economic burden of this novel disease and better identify
the cost-benefits of investing in allocating resources to
prevention and control activities. Furthermore, the com-
bination of disease severity, reimbursement proportion
and family member monthly average income was found to
be associated with patient’s hospitalization fee and these
factors should be addressed in making related health
insurance policies. Our results also pose some questions
in clinical medication administration, which need to be
further investigated. The mean hospitalization fees
presented by this study could be used for estimating the
total direct medical costs of Jiangsu Province and even
that of China after adjusting the identified determinants
aforementioned.
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